153 related articles for article (PubMed ID: 2428463)
1. Use of four monoclonal antibodies to detect tumor markers.
Kawahara M; Terasaki PI; Chia D; Johnson C; Hermes M; Tokita K
Cancer; 1986 Nov; 58(9):2008-12. PubMed ID: 2428463
[TBL] [Abstract][Full Text] [Related]
2. Detection of sialylated LewisX antigen in cancer sera using a sandwich radioimmunoassay.
Kawahara M; Chia D; Terasaki PI; Roumanas A; Sugich L; Hermes M; Iguro T
Int J Cancer; 1985 Oct; 36(4):421-5. PubMed ID: 2995258
[TBL] [Abstract][Full Text] [Related]
3. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen.
Gupta MK; Arciaga R; Bocci L; Tubbs R; Bukowski R; Deodhar SD
Cancer; 1985 Jul; 56(2):277-83. PubMed ID: 2408729
[TBL] [Abstract][Full Text] [Related]
4. Expression of monoclonal antibody-defined tumor markers in four carcinomas.
Wu JT
Ann Clin Lab Sci; 1989; 19(1):17-26. PubMed ID: 2916833
[TBL] [Abstract][Full Text] [Related]
5. Improved specificity of the CA 125 enzyme immunoassay for ovarian carcinomas by use of the ratio of CA 125 to carcinoembryonic antigen.
Wu JT; Miya T; Knight JA; Knight DP
Clin Chem; 1988 Sep; 34(9):1853-7. PubMed ID: 2458203
[TBL] [Abstract][Full Text] [Related]
6. Significance of measurement of a carbohydrate antigenic determinant 19-9 (CA 19-9) for monitoring colorectal cancer patients.
Tomoda H; Furusawa M
Jpn J Surg; 1986 Jan; 16(1):73-5. PubMed ID: 2421035
[TBL] [Abstract][Full Text] [Related]
7. [Advantages and limitations of combined assays of 4 serum markers in various types of malignant neoplasms].
Lanza E; Coda C; Ramella S; Ciambellotti E; Moro G; Cartia GL
Minerva Med; 1986 Sep; 77(34-35):1521-5. PubMed ID: 3463886
[TBL] [Abstract][Full Text] [Related]
8. CEA-related antigens: molecular biology and clinical significance.
Shively JE; Beatty JD
Crit Rev Oncol Hematol; 1985; 2(4):355-99. PubMed ID: 3886178
[No Abstract] [Full Text] [Related]
9. [Ca 19-9 and Ca 50 in the diagnosis of bronchial carcinoma: comparison with CEA].
Pecchio F; Rapellino M; Oliaro A; Moscato D; Adamo R; Albertino B; Lo Faso C; Faga C; Borasio P
Minerva Med; 1988 Mar; 79(3):183-6. PubMed ID: 2834670
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of M43: a novel cancer-associated mucin epitope.
Goodgame R; Kiefe C; Rose E; Sutton F; Brown J; Alpert E
Cancer Res; 1993 Jun; 53(12):2803-9. PubMed ID: 7684947
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Ca 12-5 as a tumor marker for gastric and colo-rectal cancer in comparison to CEA and Ca 19-9.
Quentmeier A; Schlag P; Geisen HP; Schmidt-Gayk H
Eur J Surg Oncol; 1987 Jun; 13(3):197-201. PubMed ID: 3474158
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunoassay of the CA 12 5 antigen in ovarian carcinomas: advantages compared with CA 19-9 and CEA.
Ricolleau G; Chatal JF; Fumoleau P; Kremer M; Douillard JY; Curtet C
Tumour Biol; 1984; 5(3-4):151-9. PubMed ID: 6594738
[TBL] [Abstract][Full Text] [Related]
13. [Serum carbohydrate 19-9 Tm and bronchial cancer. Comparative study with another tumor marker, carcinoembryonic antigen].
Bisset JP; Kleisbauer JP; Roux F; Treffot MJ
Pathol Biol (Paris); 1985 Jun; 33(6):672-6. PubMed ID: 3900886
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic value of tumor markers in cases of colorectal cancer: CEA and CA 19-9].
Desaive C; Servais R; Collette J; Denis D; Reginster JY; Franchimont P
Acta Gastroenterol Belg; 1987; 50(1):65-78. PubMed ID: 3480671
[No Abstract] [Full Text] [Related]
15. Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases.
Kuusela P; Jalanko H; Roberts P; Sipponen P; Mecklin JP; Pitkänen R; Mäkelä O
Br J Cancer; 1984 Feb; 49(2):135-9. PubMed ID: 6582896
[TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of three monoclonal antibody-defined tumor markers: CA 19-9, CA 50, and CA 125.
Szymendera JJ
Tumour Biol; 1986; 7(5-6):333-42. PubMed ID: 2437641
[TBL] [Abstract][Full Text] [Related]
17. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen.
Bast RC; Klug TL; Schaetzl E; Lavin P; Niloff JM; Greber TF; Zurawski VR; Knapp RC
Am J Obstet Gynecol; 1984 Jul; 149(5):553-9. PubMed ID: 6204531
[TBL] [Abstract][Full Text] [Related]
18. [Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis].
Lorenz M; Happ J; Hottenrott C; Maul FD; Baum RP; Hör G; Encke A
Nuklearmedizin; 1986 Feb; 25(1):9-14. PubMed ID: 3459133
[TBL] [Abstract][Full Text] [Related]
19. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
Yedema KA; Kenemans P; Wobbes T; van Kamp GJ; de Bruijn HW; Thomas CM; Massuger LF; Schijf CP; Bon GG; Vermorken JB
Int J Cancer; 1991 Jan; 47(2):170-9. PubMed ID: 1988362
[TBL] [Abstract][Full Text] [Related]
20. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
Suzuki H; Teshima K; Noda K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
